EKF Diagnostics Holdings (EKF)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 42.4 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.03 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | -0.4% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Ekf Diagnostics Holding PLC revenues increased 20% to L26.1M. Net income before extraordinary items totaled L236K vs. loss of L2.7M. Revenues reflect United States of America segment increase of 67% to L14M, United Kingdom segment increase of 37% to L1.4M, Poland segment increase of 14% to L1.2M. Net Income reflects Germany segment income increase from L666K to L2.8M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 1 | 2 |
EKF Diagnostics Holdings Plc, formerly International Brand Licensing plc, designs, develops, manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company is focused within the In-Vitro Diagnostic devices (IVD) market place. Other services include the servicing and distribution of other Company products under separate distribution agreements. The Company operates in Germany, United Kingdom, Ireland, Poland and Russia. On July 2, 2010, the Company acquired 100% interest of EKF-diagnostic Gmbh. On October 4, 2010, the Company acquired 100% of the share capital of Quotient Diagnostics Limited. On December 2, 2010, the Company acquired 100% of the share capital of Argutus Medical Limited. During 2010, the Company discontinued its licensing business and disposed of its portfolio of sports and lifestyle brands. In March 2012, the Company sold International Brand Licensing AG (IBL AG).
Directors: David Evans (Chmn.) 52, Julian Baines (CEO) 47, Richard Evans (Fin. Dir.) 54, Paul Foulger (Secy.) 43,
No. of Employees: 302 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 272,717,369 |
| Free Float | 236.3m (86.7%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Avon House 19 Stanwell Road Penarth, CARDIFF, CF64 2EZ, United Kingdom |
| Web | |
| Phone | +44 29 20710570 |
| Contact | () |
| Registrar | Capita Registrars (Kent) |
| Auditors | PricewaterhouseCoopers LLP |
| Wed 4:35pm | Result of AGM |
| Wed 7:00am | AGM Statement |
| 13th May | First PointMan DNA enrichment products launched |
| 15th Apr | Publication of Annual Report & Notice of AGM |
| 18th Mar | Final Results |
| 4th Mar | Establishment of EKF Molecular & Acquisition |
Recent ↓
